Here is Why Beam Therapeutics (BEAM) Appears so Attractive

Beam Therapeutics (NASDAQ:BEAM) is one of the 17 biotechnology stocks with more than 50% upside.

On January 22, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on Beam Therapeutics (NASDAQ:BEAM), with a price target of $80. This results in a highly attractive upside potential of more than 197%.

Looker_Studio/Shutterstock.com

Trucchio’s rating is based on several factors linked with the company’s clinical and regulatory progress. He noted the company’s recent agreement with the U.S. FDA to expedite the approval process for BEAM-302 in alpha-1 antitrypsin deficiency. This would enable the use of AAT biomarker data over a 12‑month horizon, which would serve as a primary basis for the future BLA.

The analyst also reflected favorably on the company’s impressive financial standing, backed by a solid cash and marketable securities balance of nearly $1.25 billion as of the end of 2025. As per his assessments, this balance should be enough to finance business operations till 2029, fund the development of BEAM-302, and cover the anticipated launch of risto-cel.

Back on January 8, Beam Therapeutics (NASDAQ:BEAM) was assigned a Neutral rating with a $28 price target by UBS analyst Michael Yee. The analyst anticipates more certainty for investors, which sets the stage for the biotech sector to do well in 2026. Going forward, he expects major catalysts and attractive pipelines to drive the segment returns.

Beam Therapeutics (NASDAQ:BEAM) is a biotechnology company that develops precision genetic medicines and also engages in gene therapies and genome editing research. Since its launch, Beam Therapeutics (NASDAQ:BEAM) has been spearheading CRISPR-based editing that facilitates the development of advanced genetic medicines.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This article is originally published at Insider Monkey.